Martine J Garnier is PhD in Pharmacology from Paul Sabatier University in Toulouse, France. She started an international career in academic research in France (INSERM, Toulouse), Italy (Milan University) and in US (Georgetown University Medical Center, Washington DC). In 1997, she receives a Research Award from the Telethon Italia Foundation for my research on Alzheimer's disease that identifies genes underpinning Estrogen neuro-protective action. Subsequently, she joins the pharmaceutical industry at SmithKline Beecham, then GlaxoSmithKline, and leads international research and development teams and projects in neuroscience and Psychiatry Drug Discovery and Development, for 12 years. In particular, she leads the development of the first-in-class novel anti-depressant pan 5-HT1 antagonists to phase II and clinical Proof-of-Concept. In 2010, she joins the services industry working for a global company as Sales and Business Development Manager, focusing on the Biotechnology industry segment. Passionate, engaged and creative, she is the founder and Managing Director of MBSVi - Medical and Biological Sciences Value Innovation- a pharmaceutical start-up company which focuses on Alzheimer Drug Discovery Innovation development and brings novel business models to accelerate the commercialisation of innovative assets. She holds a PhD in Pharmacology from Toulouse University (1991) and an Executive Master in Business Administration with a certificate in Entrepreneurship and Innovation from Paris Haute Ecole Commerciale (HEC) Management School (2014). She is the author of over 50 publications and opinion papers.